Abstract
Objectives: (1) Describe the clinical and paraclinical characteristics of patients with chronic obstructive pulmonary disease (COPD), (2) Investigate serum Sclerostin concentration and its relationship and correlation with 6-minute walking distance, symptom groups and ABE groups in patients with COPD. Materials and methods: Cross-sectional study on 43 patients with COPD admitted to the Department of Internal Medicine - Endocrinology - Rheumatology, Hue University of Medicine and Pharmacy Hospital, and the Department of Endocrinology - Pulmonology, Hue Central Hospital from July 2024 to June 2025. Results: The average age and BMI of the study group were 62.58 ± 8.05 years and 20.92 ± 3.01 kg/m2, respectively. Patients in the study group smoked 36.77 ± 18.83 packs/year. The proportion of patients in the GOLD I, II, III and IV groups were 2.3%, 58.1%, 27.9% and 14.0%, respectively. The average number of acute episodes was 1.24 ± 2.03 acute episodes/year. 58.1% of patients were in the multiple symptoms group and 41.9% of patients were in the few symptoms group. In addition, the proportions of patients in groups A, B and E were 25.6%, 34.9% and 39.5%, respectively. Serum sclerostin concentration in group E was statistically significantly lower than that in groups A and B (p < 0.05). The area under the ROC curve (AUC) of serum sclerostin concentration to predict stage E was 0.774 (p < 0.001). With a cut-off point ≤ 6.330 pmol/l, serum sclerostin concentration was able to predict stage E with a sensitivity of 88% and a specificity of 69% (95%CI: 1.57 – 5.24). There was a positive correlation between serum sclerostin concentration and 6-minute walk distance (r = 0.305, p < 0.05). Conclusion: Serum sclerostin concentration is a prognostic factor for disease stage and exercise capacity in patients with COPD.
| Published | 2026-04-30 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 02 (2026) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2026.2.790 | |
| Keywords | Chronic obstructive pulmonary disease, 6-minute walk distance, ABE stage, sclerostin |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Hue Journal of Medicine and Pharmacy
Liu M, Huo Y, Cheng Y. Mechanistic regulation of Wnt pathway-related progression of chronic obstructive pulmonary disease airway lesions. International Journal of Chronic Obstructive Pulmonary Disease. 2023:871-80.
Biasin V, Obermayer-Pietsch B. Sclerostin, bone morphogenetic protein, Wnt and the lung: a potential role beyond bone metabolism? Journal of Laboratory and Precision Medicine. 2018;3.
Dreyer TJ, Keen JA, Wells LM, Roberts SJ. Novel insights on the effect of sclerostin on bone and other organs. J Endocrinol. 2023;257(2):e220209. doi:10.1530/joe-22-0209
Lewiecki EM. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Therapeutic advances in musculoskeletal disease. 2014;6(2):48-57.
Omran A, Atanasova D, Landgren F, Magnusson P. Sclerostin: from molecule to clinical biomarker. International Journal of Molecular Sciences. 2022;23(9):4751.
Qu J, Yue L, Gao J, Yao H. Perspectives on Wnt signal pathway in the pathogenesis and therapeutics of chronic obstructive pulmonary disease. The Journal of pharmacology and experimental therapeutics. 2019;369(3):473-80.
Amado C, García-Unzueta M, Agüero J, Martín-Audera P, Fueyo P, Lavín B, et al. Associations of serum sclerostin levels with body composition, pulmonary function, and exacerbations in COPD patients. Pulmonology. 2024;30(6):512-21.
Lee J, Cho DH, Min HJ, et al. Higher sclerostin is associated with pulmonary hypertension in pre-dialysis end-stage kidney disease patients: a cross-sectional prospective observational cohort study. BMC Pulm Med. 2024;24(1):78. doi:10.1186/s12890-024-02871-8
Wang XM, Liu H, Li JY, et al. Rosamultin attenuates acute hypobaric hypoxia-induced bone injuries by regulation of sclerostin and its downstream signals. High Alt Med Biol. 2020;21(3):273-286. doi:10.1089/ham.2019.0113
Genetos DC, Toupadakis CA, Raheja LF, et al. Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem. 2010;110(2):457-467. doi:10.1002/jcb.22559
Tsukamoto M, Mori T, Nakamura E, et al. Chronic obstructive pulmonary disease severity in middle-aged and older men with osteoporosis associates with decreased bone formation. Osteoporos Sarcopenia. 2020;6(4):179-184. doi:10.1016/j.afos.2020.11.003
GOLD. Global strategy for prevention, diagnosis and management of COPD: 2024 report. 2024
Liao, Y. X., & Chen, Y. H. (2020). Twenty years of changes in the disease assessment method of the Global Initiative for Chronic Obstructive Lung Disease. Chinese Medical Journal, 133(17), 2098-2103.
Sharma, M., Joshi, S., Banjade, P., Ghamande, S. A., & Surani, S. (2024). Global initiative for chronic obstructive lung disease (GOLD) 2023 guidelines reviewed. The open respiratory medicine journal, 18, e18743064279064.
Venkatesan P. GOLD COPD report: 2025 update. The Lancet Respiratory Medicine. 2025;13(1):e7-e8.
Veverka, Vaclav, et al. (2009), "Characterization of the structural features and interactions of sclerostin", Journal of Biological Chemistry. 284(16), pp. 10890-10900.
Jaśkiewicz, Ł., Chmielewski, G., Kuna, J., Stompór, T., & Krajewska-Włodarczyk, M. (2023). The role of sclerostin in rheumatic diseases: a review. Journal of Clinical Medicine, 12(19), 6248.
Golledge, J., & Thanigaimani, S. (2022). Role of sclerostin in cardiovascular disease. Arteriosclerosis, thrombosis, and vascular biology, 42(7), e187-e202.
Alramah, T., Cherian, P., Al-Khairi, I., Abu-Farha, M., Thanaraj, T. A., Albatineh, A. N., ... & Abubaker, J. (2024). Evaluating the correlation of sclerostin levels with obesity and type 2 diabetes in a multiethnic population living in Kuwait. Frontiers in Endocrinology, 15, 1392675.
Jenkins SC. 6-Minute walk test in patients with COPD: clinical applications in pulmonary rehabilitation. Physiotherapy. 2007;93(3):175-82.
Ghofraniha L, Dalir Sani Z, Vakilian F, Khajedalooyi M, Arabshahi ZJ. The six-minute walk test (6MWT) for the evaluation of pulmonary diseases. Journal of Cardio-Thoracic Medicine. 2015;3(2):284-7.